- Home
- Publications
- Publication Search
- Publication Details
Title
Targeting mTOR for cancer therapy
Authors
Keywords
Cancer, Drug resistance, mTOR, Oncogene, Targeted therapy
Journal
Journal of Hematology & Oncology
Volume 12, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2019-07-05
DOI
10.1186/s13045-019-0754-1
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Targeting mTOR with MLN0128 Overcomes Rapamycin and Chemoresistant Primary Effusion Lymphoma
- (2019) Carolina Caro-Vegas et al. mBio
- Chronic TGF-β exposure drives stabilized EMT, tumor stemness, and cancer drug resistance with vulnerability to bitopic mTOR inhibition
- (2019) Yoko Katsuno et al. Science Signaling
- Properties of FDA-approved small molecule protein kinase inhibitors
- (2019) Robert Roskoski PHARMACOLOGICAL RESEARCH
- Identifying and targeting cancer stem cells in leiomyosarcoma: prognostic impact and role to overcome secondary resistance to PI3K/mTOR inhibition
- (2019) Benjamin Fourneaux et al. Journal of Hematology & Oncology
- The regulatory protein GADD34 inhibits TRAIL-induced apoptosis via TRAF6/ERK-dependent stabilization of myeloid cell leukemia 1 in liver cancer cells
- (2019) Peiying Song et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- CDK12 phosphorylates 4E-BP1 to enable mTORC1-dependent translation and mitotic genome stability
- (2019) Seung H. Choi et al. GENES & DEVELOPMENT
- OUP accepted manuscript
- (2018) ANNALS OF ONCOLOGY
- Induction of MEK/ERK activity by AZD8055 confers acquired resistance in neuroblastoma
- (2018) Dong-qing Xu et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Phase II study of everolimus (RAD001) monotherapy as first-line treatment in advanced biliary tract cancer with biomarker exploration: the RADiChol Study
- (2018) David K. Lau et al. BRITISH JOURNAL OF CANCER
- Phase 1/2 trial of temsirolimus and sorafenib in the treatment of patients with recurrent glioblastoma: North Central Cancer Treatment Group Study/Alliance N0572
- (2018) David Schiff et al. CANCER
- The GSK3 Signaling Axis Regulates Adaptive Glutamine Metabolism in Lung Squamous Cell Carcinoma
- (2018) Milica Momcilovic et al. CANCER CELL
- Phosphorylation of AKT and ERK1/2 and mutations of PIK3CA and PTEN are predictive of breast cancer cell sensitivity to everolimus in vitro
- (2018) Valentina Citi et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Metabolic Determinants of Sensitivity to Phosphatidylinositol 3-Kinase Pathway Inhibitor in Small-Cell Lung Carcinoma
- (2018) Hideki Makinoshima et al. CANCER RESEARCH
- Unmasking the impact of Rictor in cancer: novel insights of mTORC2 complex
- (2018) Anastasios Gkountakos et al. CARCINOGENESIS
- Cryo-EM structure of human mTOR complex 2
- (2018) Xizi Chen et al. CELL RESEARCH
- Combined CDK4/6 and pan-mTOR inhibition is synergistic against intrahepatic cholangiocarcinoma
- (2018) Xinhua Song et al. CLINICAL CANCER RESEARCH
- Canonical signaling and nuclear activity of mTOR-a teamwork effort to regulate metabolism and cell growth
- (2018) Vincent Giguère FEBS Journal
- Modulation of TORC2 Signaling by a Conserved Lkb1 Signaling Axis in Budding Yeast
- (2018) Maria Alcaide-Gavilán et al. GENETICS
- Activation of WNT/β-catenin signaling results in resistance to a dual PI3K/mTOR inhibitor in colorectal cancer cells harboring PIK3CA mutations
- (2018) Ye-Lim Park et al. INTERNATIONAL JOURNAL OF CANCER
- A phase II study of the dual mTOR inhibitor MLN0128 in patients with metastatic castration resistant prostate cancer
- (2018) Laura Graham et al. INVESTIGATIONAL NEW DRUGS
- Metabolite identification and pharmacokinetic profiling of PP242, an ATP-competitive inhibitor of mTOR using ultra high-performance liquid chromatography and mass spectrometry
- (2018) Md. Mamunur Rashid et al. JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES
- A loss-of-function genetic screening reveals synergistic targeting of AKT/mTOR and WTN/β-catenin pathways for treatment of AML with high PRL-3 phosphatase
- (2018) Jianbiao Zhou et al. Journal of Hematology & Oncology
- NF-κB signaling and its relevance to the treatment of mantle cell lymphoma
- (2018) Swathi Balaji et al. Journal of Hematology & Oncology
- Characterization and validation of potential therapeutic targets based on the molecular signature of patient-derived xenografts in gastric cancer
- (2018) Zuhua Chen et al. Journal of Hematology & Oncology
- Complex roles of the old drug aspirin in cancer chemoprevention and therapy
- (2018) Hui Hua et al. MEDICINAL RESEARCH REVIEWS
- Kinome rewiring reveals AURKA limits PI3K-pathway inhibitor efficacy in breast cancer
- (2018) Hayley J. Donnella et al. Nature Chemical Biology
- Functional screening of FGFR4-driven tumorigenesis identifies PI3K/mTOR inhibition as a therapeutic strategy in rhabdomyosarcoma
- (2018) Timothy McKinnon et al. ONCOGENE
- RICTOR gene amplification is correlated with metastasis and therapeutic resistance in triple-negative breast cancer
- (2018) Said El Shamieh et al. PHARMACOGENOMICS
- ATR kinase inhibitors NVP-BEZ235 and AZD6738 effectively penetrate the brain after systemic administration
- (2018) Guido Fròsina et al. Radiation Oncology
- Cap-Independent Translation: What’s in a Name?
- (2018) Ivan N. Shatsky et al. TRENDS IN BIOCHEMICAL SCIENCES
- Dual PI3K/mTOR inhibitor BEZ235 as a promising therapeutic strategy against paclitaxel-resistant gastric cancer via targeting PI3K/Akt/mTOR pathway
- (2018) Dongshao Chen et al. Cell Death & Disease
- Modulation of TORC2 Signaling by a Conserved Lkb1 Signaling Axis in Budding Yeast
- (2018) Maria Alcaide-Gavilán et al. GENETICS
- Voxtalisib (XL765) in patients with relapsed or refractory non-Hodgkin lymphoma or chronic lymphocytic leukaemia: an open-label, phase 2 trial
- (2018) Jennifer R Brown et al. Lancet Haematology
- Imatinib and Everolimus in Patients With Progressing Advanced Chordoma: A Phase 2 Clinical Study
- (2018) Silvia Stacchiotti et al. CANCER
- Everolimus-based combination therapies for HR+, HER2− metastatic breast cancer
- (2018) Joyce O'Shaughnessy et al. CANCER TREATMENT REVIEWS
- mTORC2 modulates the amplitude and duration of GFAT1 Ser243 phosphorylation to maintain flux through the hexosamine pathway during starvation
- (2018) Joseph G. Moloughney et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Mitochondria-targeted drugs stimulate mitophagy and abrogate colon cancer cell proliferation
- (2018) Kathleen A. Boyle et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Organoid technology and applications in cancer research
- (2018) Hanxiao Xu et al. Journal of Hematology & Oncology
- A Patient-derived Xenograft Model of Pancreatic Neuroendocrine Tumors Identifies Sapanisertib as a Possible New Treatment for Everolimus-Resistant Tumors
- (2018) Chester E. Chamberlain et al. MOLECULAR CANCER THERAPEUTICS
- The novel, catalytic mTORC1/2 inhibitor PQR620 and the PI3K/mTORC1/2 inhibitor PQR530 effectively cross the blood-brain barrier and increase seizure threshold in a mouse model of chronic epilepsy
- (2018) Claudia Brandt et al. NEUROPHARMACOLOGY
- mTORC1/2 inhibition re-sensitizes platinum-resistant ovarian cancer by disrupting selective translation of DNA damage and survival mRNAs
- (2018) Gizelka David-West et al. Oncotarget
- ETV7 is an essential component of a rapamycin-insensitive mTOR complex in cancer
- (2018) Franklin C. Harwood et al. Science Advances
- A phase Ib dose-escalation and expansion study of the oral MEK inhibitor pimasertib and PI3K/MTOR inhibitor voxtalisib in patients with advanced solid tumours
- (2018) Alison M. Schram et al. BRITISH JOURNAL OF CANCER
- Ubiquitination of Rheb governs growth factor-induced mTORC1 activation
- (2018) Lu Deng et al. CELL RESEARCH
- mTORC1/2 and Protein Translation Regulate Levels of CHK1 and the Sensitivity to CHK1 Inhibitors in Ewing Sarcoma Cells
- (2018) Stacia L. Koppenhafer et al. MOLECULAR CANCER THERAPEUTICS
- MTORC1/2 inhibition as a therapeutic strategy for PIK3CA mutant cancers
- (2018) Stephanie L. Fricke et al. MOLECULAR CANCER THERAPEUTICS
- Phase 2 trial of everolimus and letrozole in relapsed estrogen receptor-positive high-grade ovarian cancers
- (2017) Gerardo Colon-Otero et al. GYNECOLOGIC ONCOLOGY
- ABC Transporters in Cancer Stem Cells: Beyond Chemoresistance
- (2017) Romana-Rea Begicevic et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Lipid sensing by mTOR complexes viade novosynthesis of phosphatidic acid
- (2017) Deepak Menon et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Localization of mTORC2 activity inside cells
- (2017) Michael Ebner et al. JOURNAL OF CELL BIOLOGY
- Circulating mutational portrait of cancer: manifestation of aggressive clonal events in both early and late stages
- (2017) Meng Yang et al. Journal of Hematology & Oncology
- Metformin potentiates the effect of arsenic trioxide suppressing intrahepatic cholangiocarcinoma: roles of p38 MAPK, ERK3, and mTORC1
- (2017) Sunbin Ling et al. Journal of Hematology & Oncology
- 5-(4,6-Dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine (PQR309), a Potent, Brain-Penetrant, Orally Bioavailable, Pan-Class I PI3K/mTOR Inhibitor as Clinical Candidate in Oncology
- (2017) Florent Beaufils et al. JOURNAL OF MEDICINAL CHEMISTRY
- Phosphorylation by mTORC1 stablizes Skp2 and regulates its oncogenic function in gastric cancer
- (2017) Qirong Geng et al. Molecular Cancer
- mTOR Controls Mitochondrial Dynamics and Cell Survival via MTFP1
- (2017) Masahiro Morita et al. MOLECULAR CELL
- K-Ras mutation and amplification status is predictive of resistance and high basal pAKT is predictive of sensitivity to everolimus in biliary tract cancer cell lines
- (2017) Yvonne Yeung et al. Molecular Oncology
- Overexpression of ATP-Binding Cassette Subfamily G Member 2 Confers Resistance to Phosphatidylinositol 3-Kinase Inhibitor PF-4989216 in Cancer Cells
- (2017) Chung-Pu Wu et al. MOLECULAR PHARMACEUTICS
- TRAF2 and OTUD7B govern a ubiquitin-dependent switch that regulates mTORC2 signalling
- (2017) Bin Wang et al. NATURE
- SZT2 dictates GATOR control of mTORC1 signalling
- (2017) Min Peng et al. NATURE
- KICSTOR recruits GATOR1 to the lysosome and is necessary for nutrients to regulate mTORC1
- (2017) Rachel L. Wolfson et al. NATURE
- The androgen receptor is a negative regulator of eIF4E phosphorylation at S209: implications for the use of mTOR inhibitors in advanced prostate cancer
- (2017) L S D'Abronzo et al. ONCOGENE
- Tumor microenvironment confers mTOR inhibitor resistance in invasive intestinal adenocarcinoma
- (2017) T Fujishita et al. ONCOGENE
- Crystal structure of the human lysosomal mTORC1 scaffold complex and its impact on signaling
- (2017) Mariana E. G. de Araujo et al. SCIENCE
- Lysosomal cholesterol activates mTORC1 via an SLC38A9–Niemann-Pick C1 signaling complex
- (2017) Brian M. Castellano et al. SCIENCE
- Genetic and epigenetic inactivation of SESTRIN1 controls mTORC1 and response to EZH2 inhibition in follicular lymphoma
- (2017) Elisa Oricchio et al. Science Translational Medicine
- Snail determines the therapeutic response to mTOR kinase inhibitors by transcriptional repression of 4E-BP1
- (2017) Jun Wang et al. Nature Communications
- Cryo-EM structure of Saccharomyces cerevisiae target of rapamycin complex 2
- (2017) Manikandan Karuppasamy et al. Nature Communications
- The mTORC1 Signaling Network Senses Changes in Cellular Purine Nucleotide Levels
- (2017) Gerta Hoxhaj et al. Cell Reports
- Potent efficacy of combined PI3K/mTOR and JAK or ABL inhibition in murine xenograft models of Ph-like acute lymphoblastic leukemia
- (2016) Sarah K. Tasian et al. BLOOD
- PI3K–mTOR Pathway Inhibition Exhibits Efficacy Against High-grade Glioma in Clinically Relevant Mouse Models
- (2016) Fan Lin et al. CLINICAL CANCER RESEARCH
- Mutations in TSC1, TSC2, and MTOR Are Associated with Response to Rapalogs in Patients with Metastatic Renal Cell Carcinoma
- (2016) D. J. Kwiatkowski et al. CLINICAL CANCER RESEARCH
- A Randomised Phase 2 Study of AZD2014 Versus Everolimus in Patients with VEGF-Refractory Metastatic Clear Cell Renal Cancer
- (2016) Thomas Powles et al. EUROPEAN UROLOGY
- A randomized phase II non-comparative study of PF-04691502 and gedatolisib (PF-05212384) in patients with recurrent endometrial cancer
- (2016) Josep María del Campo et al. GYNECOLOGIC ONCOLOGY
- A phase Ib dose-escalation study of the MEK inhibitor trametinib in combination with the PI3K/mTOR inhibitor GSK2126458 in patients with advanced solid tumors
- (2016) J. E. Grilley-Olson et al. INVESTIGATIONAL NEW DRUGS
- Mechanistically distinct cancer-associated mTOR activation clusters predict sensitivity to rapamycin
- (2016) Jianing Xu et al. JOURNAL OF CLINICAL INVESTIGATION
- Randomized Open-Label Phase II Trial of Apitolisib (GDC-0980), a Novel Inhibitor of the PI3K/Mammalian Target of Rapamycin Pathway, Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma
- (2016) Thomas Powles et al. JOURNAL OF CLINICAL ONCOLOGY
- Rheb1 promotes tumor progression through mTORC1 in MLL-AF9-initiated murine acute myeloid leukemia
- (2016) Yanan Gao et al. Journal of Hematology & Oncology
- Dual mTORC1/2 Inhibition as a Novel Strategy for the Resensitization and Treatment of Platinum-Resistant Ovarian Cancer
- (2016) Fernanda Musa et al. MOLECULAR CANCER THERAPEUTICS
- Characterization of LY3023414, a Novel PI3K/mTOR Dual Inhibitor Eliciting Transient Target Modulation to Impede Tumor Growth
- (2016) M. C. Smith et al. MOLECULAR CANCER THERAPEUTICS
- mTORC2 Responds to Glutamine Catabolite Levels to Modulate the Hexosamine Biosynthesis Enzyme GFAT1
- (2016) Joseph G. Moloughney et al. MOLECULAR CELL
- A Phase Ib Study of BEZ235, a Dual Inhibitor of Phosphatidylinositol 3-Kinase (PI3K) and Mammalian Target of Rapamycin (mTOR), in Patients With Advanced Renal Cell Carcinoma
- (2016) Maria I. Carlo et al. ONCOLOGIST
- mTORC1 induces purine synthesis through control of the mitochondrial tetrahydrofolate cycle
- (2016) I. Ben-Sahra et al. SCIENCE
- PI3K/Akt promotes feedforward mTORC2 activation through IKKα
- (2016) Han C. Dan et al. Oncotarget
- TP53 mutated glioblastoma stem-like cell cultures are sensitive to dual mTORC1/2 inhibition while resistance in TP53 wild type cultures can be overcome by combined inhibition of mTORC1/2 and Bcl-2
- (2016) Subramanian Venkatesan et al. Oncotarget
- 4.4 Å Resolution Cryo-EM structure of human mTOR Complex 1
- (2016) Huirong Yang et al. Protein & Cell
- Everolimus combined with R-CHOP-21 for new, untreated, diffuse large B-cell lymphoma (NCCTG 1085 [Alliance]): safety and efficacy results of a phase 1 and feasibility trial
- (2016) Patrick B Johnston et al. Lancet Haematology
- Compensatory Increase of Transglutaminase 2 Is Responsible for Resistance to mTOR Inhibitor Treatment
- (2016) Jingwen Cao et al. PLoS One
- Clinical usefulness of PI3K/Akt/mTOR genotyping in companion with other clinical variables in metastatic renal cell carcinoma patients treated with everolimus in the second and subsequent lines
- (2015) L. Bodnar et al. ANNALS OF ONCOLOGY
- EVERSUN: a phase 2 trial of alternating sunitinib and everolimus as first-line therapy for advanced renal cell carcinoma
- (2015) I. D. Davis et al. ANNALS OF ONCOLOGY
- In vitro activity of the mTOR inhibitor everolimus, in a large panel of breast cancer cell lines and analysis for predictors of response
- (2015) Sara A. Hurvitz et al. BREAST CANCER RESEARCH AND TREATMENT
- Therapeutic potential of mTOR inhibitors for targeting cancer stem cells
- (2015) Maria Giovanna Francipane et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Everolimus combined with gefitinib in patients with metastatic castration-resistant prostate cancer: Phase 1/2 results and signaling pathway implications
- (2015) Dana E. Rathkopf et al. CANCER
- NVP-BEZ235, a novel dual PI3K–mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells
- (2015) Zhiyun Yu et al. CANCER LETTERS
- mTOR inhibitors counteract tamoxifen-induced activation of breast cancer stem cells
- (2015) Govindasamy-Muralidharan Karthik et al. CANCER LETTERS
- Treatment of Triple-Negative Breast Cancer with TORC1/2 Inhibitors Sustains a Drug-Resistant and Notch-Dependent Cancer Stem Cell Population
- (2015) Neil E. Bhola et al. CANCER RESEARCH
- mTORC2 promotes type I insulin-like growth factor receptor and insulin receptor activation through the tyrosine kinase activity of mTOR
- (2015) Yancun Yin et al. CELL RESEARCH
- Multiple amino acid sensing inputs to mTORC1
- (2015) Mitsugu Shimobayashi et al. CELL RESEARCH
- Serial Next-Generation Sequencing of Circulating Cell-Free DNA Evaluating Tumor Clone Response To Molecularly Targeted Drug Administration
- (2015) J. S. Frenel et al. CLINICAL CANCER RESEARCH
- MEK Inhibitor PD-0325901 Overcomes Resistance to PI3K/mTOR Inhibitor PF-5212384 and Potentiates Antitumor Effects in Human Head and Neck Squamous Cell Carcinoma
- (2015) S. Mohan et al. CLINICAL CANCER RESEARCH
- Radiation Enhancement of Head and Neck Squamous Cell Carcinoma by the Dual PI3K/mTOR Inhibitor PF-05212384
- (2015) A. J. Leiker et al. CLINICAL CANCER RESEARCH
- Modulation of Glucocorticoid Resistance in Pediatric T-cell Acute Lymphoblastic Leukemia by Increasing BIM Expression with the PI3K/mTOR Inhibitor BEZ235
- (2015) C. P. Hall et al. CLINICAL CANCER RESEARCH
- Antitumor activity of a combination of dual PI3K/mTOR inhibitor SAR245409 and selective MEK1/2 inhibitor pimasertib in endometrial carcinomas
- (2015) Kanako Inaba et al. GYNECOLOGIC ONCOLOGY
- Target of Rapamycin Complex 2 Regulates Actin Polarization and Endocytosis via Multiple Pathways
- (2015) Delphine Rispal et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Compensatory glutamine metabolism promotes glioblastoma resistance to mTOR inhibitor treatment
- (2015) Kazuhiro Tanaka et al. JOURNAL OF CLINICAL INVESTIGATION
- Defining the Domain Arrangement of the Mammalian Target of Rapamycin Complex Component Rictor Protein
- (2015) Ping Zhou et al. JOURNAL OF COMPUTATIONAL BIOLOGY
- Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: a non-randomised phase 2 clinical trial
- (2015) Giovanni Grignani et al. LANCET ONCOLOGY
- AZD2014, an Inhibitor of mTORC1 and mTORC2, Is Highly Effective in ER+ Breast Cancer When Administered Using Intermittent or Continuous Schedules
- (2015) S. M. Guichard et al. MOLECULAR CANCER THERAPEUTICS
- Skp2-Mediated RagA Ubiquitination Elicits a Negative Feedback to Prevent Amino-Acid-Dependent mTORC1 Hyperactivation by Recruiting GATOR1
- (2015) Guoxiang Jin et al. MOLECULAR CELL
- The Ubiquitination of RagA GTPase by RNF152 Negatively Regulates mTORC1 Activation
- (2015) Lu Deng et al. MOLECULAR CELL
- CDK1 substitutes for mTOR kinase to activate mitotic cap-dependent protein translation
- (2015) Masahiro Shuda et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Architecture of human mTOR complex 1
- (2015) C. H. S. Aylett et al. SCIENCE
- Lysosomal amino acid transporter SLC38A9 signals arginine sufficiency to mTORC1
- (2015) S. Wang et al. SCIENCE
- Sestrin2 is a leucine sensor for the mTORC1 pathway
- (2015) R. L. Wolfson et al. SCIENCE
- Current treatment strategies for inhibiting mTOR in cancer
- (2015) Francesca Chiarini et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- PtdIns(3,4,5)P3-Dependent Activation of the mTORC2 Kinase Complex
- (2015) P. Liu et al. Cancer Discovery
- Point mutations of the mTOR-RHEB pathway in renal cell carcinoma
- (2015) Arindam P. Ghosh et al. Oncotarget
- Selective targeting of human colon cancer stem-like cells by the mTOR inhibitor Torin-1
- (2015) Maria Giovanna Francipane et al. Oncotarget
- Catalytic mTOR inhibitors can overcome intrinsic and acquired resistance to allosteric mTOR inhibitors
- (2015) Burhan Hassan et al. Oncotarget
- Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2†
- (2014) M. Piccart et al. ANNALS OF ONCOLOGY
- The dual PI3K/mTOR inhibitor PKI-587 enhances sensitivity to cetuximab in EGFR-resistant human head and neck cancer models
- (2014) V D'Amato et al. BRITISH JOURNAL OF CANCER
- PI3K/mTOR Dual Inhibitor VS-5584 Preferentially Targets Cancer Stem Cells
- (2014) V. N. Kolev et al. CANCER RESEARCH
- Sestrins Function as Guanine Nucleotide Dissociation Inhibitors for Rag GTPases to Control mTORC1 Signaling
- (2014) Min Peng et al. CELL
- P-Glycoprotein, CYP3A, and Plasma Carboxylesterase Determine Brain and Blood Disposition of the mTOR Inhibitor Everolimus (Afinitor) in Mice
- (2014) S. C. Tang et al. CLINICAL CANCER RESEARCH
- Phase I study of PF-04691502, a small-molecule, oral, dual inhibitor of PI3K and mTOR, in patients with advanced cancer
- (2014) Carolyn D. Britten et al. INVESTIGATIONAL NEW DRUGS
- Dual PI3K/mTOR Inhibitors, GSK2126458 and PKI-587, Suppress Tumor Progression and Increase Radiosensitivity in Nasopharyngeal Carcinoma
- (2014) T. Liu et al. MOLECULAR CANCER THERAPEUTICS
- Characterization of the Activity of the PI3K/mTOR Inhibitor XL765 (SAR245409) in Tumor Models with Diverse Genetic Alterations Affecting the PI3K Pathway
- (2014) P. Yu et al. MOLECULAR CANCER THERAPEUTICS
- MLN0128, an ATP-Competitive mTOR Kinase Inhibitor with Potent In Vitro and In Vivo Antitumor Activity, as Potential Therapy for Bone and Soft-Tissue Sarcoma
- (2014) E. K. Slotkin et al. MOLECULAR CANCER THERAPEUTICS
- The metabolite α-ketoglutarate extends lifespan by inhibiting ATP synthase and TOR
- (2014) Randall M. Chin et al. NATURE
- Discovery and saturation analysis of cancer genes across 21 tumour types
- (2014) Michael S. Lawrence et al. NATURE
- Phosphorylation of eIF4E promotes EMT and metastasis via translational control of SNAIL and MMP-3
- (2014) N Robichaud et al. ONCOGENE
- Resistance to dual blockade of the kinases PI3K and mTOR in KRAS-mutant colorectal cancer models results in combined sensitivity to inhibition of the receptor tyrosine kinase EGFR
- (2014) P. J. Belmont et al. Science Signaling
- mTORC1 signaling controls multiple steps in ribosome biogenesis
- (2014) Valentina Iadevaia et al. SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY
- A Diverse Array of Cancer-Associated MTOR Mutations Are Hyperactivating and Can Predict Rapamycin Sensitivity
- (2014) B. C. Grabiner et al. Cancer Discovery
- The Sestrins Interact with GATOR2 to Negatively Regulate the Amino-Acid-Sensing Pathway Upstream of mTORC1
- (2014) Lynne Chantranupong et al. Cell Reports
- Sestrins Inhibit mTORC1 Kinase Activation through the GATOR Complex
- (2014) Anita Parmigiani et al. Cell Reports
- Everolimus Plus Exemestane in Postmenopausal Patients with HR+ Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis
- (2013) Denise A. Yardley et al. ADVANCES IN THERAPY
- Rapamycin-mediated lifespan increase in mice is dose and sex dependent and metabolically distinct from dietary restriction
- (2013) Richard A. Miller et al. AGING CELL
- A phase 2 study of everolimus combined with trastuzumab and paclitaxel in patients with HER2-overexpressing advanced breast cancer that progressed during prior trastuzumab and taxane therapy
- (2013) Sara A. Hurvitz et al. BREAST CANCER RESEARCH AND TREATMENT
- Ridaforolimus as a single agent in advanced endometrial cancer: results of a single-arm, phase 2 trial
- (2013) N Colombo et al. BRITISH JOURNAL OF CANCER
- Radioresistant Cancer Cells Can Be Conditioned to Enter Senescence by mTOR Inhibition
- (2013) H. Y. Nam et al. CANCER RESEARCH
- The ATP-Competitive mTOR Inhibitor INK128 Enhances In Vitro and In Vivo Radiosensitivity of Pancreatic Carcinoma Cells
- (2013) T. J. Hayman et al. CLINICAL CANCER RESEARCH
- mTOR complex 2 phosphorylates IMP1 cotranslationally to promote IGF2 production and the proliferation of mouse embryonic fibroblasts
- (2013) N. Dai et al. GENES & DEVELOPMENT
- Adaptation to mTOR kinase inhibitors by amplification of eIF4E to maintain cap-dependent translation
- (2013) Claire L. Cope et al. JOURNAL OF CELL SCIENCE
- Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trial
- (2013) Gary K Schwartz et al. LANCET ONCOLOGY
- K63 Polyubiquitination and Activation of mTOR by the p62-TRAF6 Complex in Nutrient-Activated Cells
- (2013) Juan F. Linares et al. MOLECULAR CELL
- Sin1 phosphorylation impairs mTORC2 complex integrity and inhibits downstream Akt signalling to suppress tumorigenesis
- (2013) Pengda Liu et al. NATURE CELL BIOLOGY
- The mTORC1/mTORC2 inhibitor AZD2014 enhances the radiosensitivity of glioblastoma stem-like cells
- (2013) Jenna Kahn et al. NEURO-ONCOLOGY
- Incomplete inhibition of phosphorylation of 4E-BP1 as a mechanism of primary resistance to ATP-competitive mTOR inhibitors
- (2013) G S Ducker et al. ONCOGENE
- Glycogen synthase kinase-3β positively regulates protein synthesis and cell proliferation through the regulation of translation initiation factor 4E-binding protein 1
- (2013) S Shin et al. ONCOGENE
- XPLN is an endogenous inhibitor of mTORC2
- (2013) N. Khanna et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Stimulation of de Novo Pyrimidine Synthesis by Growth Signaling Through mTOR and S6K1
- (2013) I. Ben-Sahra et al. SCIENCE
- Quantitative Phosphoproteomics Reveal mTORC1 Activates de Novo Pyrimidine Synthesis
- (2013) A. M. Robitaille et al. SCIENCE
- A Tumor Suppressor Complex with GAP Activity for the Rag GTPases That Signal Amino Acid Sufficiency to mTORC1
- (2013) L. Bar-Peled et al. SCIENCE
- Phosphatidic acid and lipid-sensing by mTOR
- (2013) David A. Foster TRENDS IN ENDOCRINOLOGY AND METABOLISM
- PDK1 Signaling Toward PLK1-MYC Activation Confers Oncogenic Transformation, Tumor-Initiating Cell Activation, and Resistance to mTOR-Targeted Therapy
- (2013) J. Tan et al. Cancer Discovery
- Investigational drug MLN0128, a novel TORC1/2 inhibitor, demonstrates potent oral antitumor activity in human breast cancer xenograft models
- (2012) Yesim Gökmen-Polar et al. BREAST CANCER RESEARCH AND TREATMENT
- PIK3CA Mutation H1047R Is Associated with Response to PI3K/AKT/mTOR Signaling Pathway Inhibitors in Early-Phase Clinical Trials
- (2012) F. Janku et al. CANCER RESEARCH
- PIK3CA/PTEN Mutations and Akt Activation As Markers of Sensitivity to Allosteric mTOR Inhibitors
- (2012) F. Meric-Bernstam et al. CLINICAL CANCER RESEARCH
- Everolimus in combination with rituximab induces complete responses in heavily pretreated diffuse large B-cell lymphoma
- (2012) J. A. Barnes et al. HAEMATOLOGICA
- Intestinal Cell Kinase (ICK) Promotes Activation of mTOR Complex 1 (mTORC1) through Phosphorylation of Raptor Thr-908
- (2012) Di Wu et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- A phase 1 study of everolimus and sorafenib for metastatic clear cell renal cell carcinoma
- (2011) Andrea L. Harzstark et al. CANCER
- Activation of mTORC2 by Association with the Ribosome
- (2011) Vittoria Zinzalla et al. CELL
- Phase I Trial of Cixutumumab Combined with Temsirolimus in Patients with Advanced Cancer
- (2011) Aung Naing et al. CLINICAL CANCER RESEARCH
- Everolimus for Advanced Pancreatic Neuroendocrine Tumors
- (2011) James C. Yao et al. NEW ENGLAND JOURNAL OF MEDICINE
- Transglutaminase 2: a multi-functional protein in multiple subcellular compartments
- (2010) Donghyun Park et al. AMINO ACIDS
- Transglutaminase 2: A multi-tasking protein in the complex circuitry of inflammation and cancer
- (2010) Kapil Mehta et al. BIOCHEMICAL PHARMACOLOGY
- Ragulator-Rag Complex Targets mTORC1 to the Lysosomal Surface and Is Necessary for Its Activation by Amino Acids
- (2010) Yasemin Sancak et al. CELL
- The TSC1 and TSC2 tumor suppressors are required for proper ER stress response and protect cells from ER stress-induced apoptosis
- (2010) Y J Kang et al. CELL DEATH AND DIFFERENTIATION
- ERK1/2 Phosphorylate Raptor to Promote Ras-dependent Activation of mTOR Complex 1 (mTORC1)
- (2010) Audrey Carriere et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus
- (2010) Federica Di Nicolantonio et al. JOURNAL OF CLINICAL INVESTIGATION
- Bis(morpholino-1,3,5-triazine) Derivatives: Potent Adenosine 5′-Triphosphate Competitive Phosphatidylinositol-3-kinase/Mammalian Target of Rapamycin Inhibitors: Discovery of Compound26(PKI-587), a Highly Efficacious Dual Inhibitor
- (2010) Aranapakam M. Venkatesan et al. JOURNAL OF MEDICINAL CHEMISTRY
- Structure of the Human mTOR Complex I and Its Implications for Rapamycin Inhibition
- (2010) Calvin K. Yip et al. MOLECULAR CELL
- mTOR associates with TFIIIC, is found at tRNA and 5S rRNA genes, and targets their repressor Maf1
- (2010) T. Kantidakis et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Discovery of GSK2126458, a Highly Potent Inhibitor of PI3K and the Mammalian Target of Rapamycin
- (2010) Steven D. Knight et al. ACS Medicinal Chemistry Letters
- Characterization of Rictor Phosphorylation Sites Reveals Direct Regulation of mTOR Complex 2 by S6K1
- (2009) C. C. Dibble et al. MOLECULAR AND CELLULAR BIOLOGY
- mTORC1-Activated S6K1 Phosphorylates Rictor on Threonine 1135 and Regulates mTORC2 Signaling
- (2009) L.-A. Julien et al. MOLECULAR AND CELLULAR BIOLOGY
- Rapamycin fed late in life extends lifespan in genetically heterogeneous mice
- (2009) David E. Harrison et al. NATURE
- Active-Site Inhibitors of mTOR Target Rapamycin-Resistant Outputs of mTORC1 and mTORC2
- (2009) Morris E Feldman et al. PLOS BIOLOGY
- Rictor and Integrin-Linked Kinase Interact and Regulate Akt Phosphorylation and Cancer Cell Survival
- (2008) P. C. McDonald et al. CANCER RESEARCH
- Oncogenic MAPK Signaling Stimulates mTORC1 Activity by Promoting RSK-Mediated Raptor Phosphorylation
- (2008) Audrey Carrière et al. CURRENT BIOLOGY
- Phase I Trial of the Novel Mammalian Target of Rapamycin Inhibitor Deforolimus (AP23573; MK-8669) Administered Intravenously Daily for 5 Days Every 2 Weeks to Patients With Advanced Malignancies
- (2008) Monica M. Mita et al. JOURNAL OF CLINICAL ONCOLOGY
- ATF6 -Rheb-mTOR signaling promotes survival of dormant tumor cells in vivo
- (2008) D. M. Schewe et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- FBXW7 Targets mTOR for Degradation and Cooperates with PTEN in Tumor Suppression
- (2008) Jian-Hua Mao et al. SCIENCE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started